Next Article in Journal
Massive Data Management and Sharing Module for Connectome Reconstruction
Previous Article in Journal
Parental Education and Youth Inhibitory Control in the Adolescent Brain Cognitive Development (ABCD) Study: Blacks’ Diminished Returns
Previous Article in Special Issue
A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Brain Sciences
Volume 10
Issue 5
10.3390/brainsci10050313
brainsci-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Erratum to Brain Sci. 2020, 10(3), 176.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Erratum

Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176

by
Javier Pagonabarraga
1,2,3,*,
José Matías Arbelo
4,5,
Francisco Grandas
6,7,
Maria-Rosario Luquin
8,9,
Pablo Martínez Martín
10,11,
Maria Cruz Rodriguez-Oroz
12,13,
Francesc Valldeoriola
14,15 and
Jaime Kulisevsky
1,2,3,16,17
1
Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
2
Department of Medicine, Autonomous University of Barcelona, 08193 Barcelona, Spain
3
Centro de Investigación en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain
4
Movement Disorders Unit, Neurology Department, Hospital Universitario San Roque, 35001 Las Palmas, Spain
5
Department of Medicine, Universidad Fernando Pessoa-Canarias, 35450 Las Palmas, Spain
6
Movement Disorders Unit-CSUR, Neurology Department, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
7
Department of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain
8
Movement Disorders Unit, Clínica Universidad de Navarra (CUN), 31008 Pamplona, Spain
9
Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain
10
Instituto de Salud Carlos III, 28029 Madrid, Spain
11
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain
12
Neurology and Neuroscience Unit, Clínica Universidad de Navarra (CUN), 31008 Pamplona, Spain
13
Centre for Applied Medical Research (CIMA), 31008 Pamplona, Spain
14
Neurosciences Institut, Hospital Clinic de Barcelona, 08036 Barcelona, Spain
15
Department of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain
16
Biomedical Research Institute (IIB-Sant Pau), 08041 Barcelona, Spain
17
Department of Medicine, Universitat Oberta de Catalunya, 08018 Barcelona, Spain
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Brain Sci. 2020, 10(5), 313; https://doi.org/10.3390/brainsci10050313
Submission received: 11 May 2020 / Accepted: 15 May 2020 / Published: 22 May 2020
(This article belongs to the Special Issue Frontiers in Parkinson’s Disease (PD))
Versions Notes
We would like to submit the following erratum to our recently published paper [1] due to the errors in the abstract. We request (1) the removal of the word “motor” from the first line of the abstract, so that the sentence reads: “Safinamide is an approved drug for the treatment of fluctuations in Parkinson’s disease (PD)”, and (2) that the word “OFF” is changed to “ON” in line 6 of the abstract, so that the sentence reads: “Safinamide significantly improves the mean daily ON time without troublesome dyskinesias.”
We apologize for any inconvenience caused to our readers.

Conflicts of Interest

The authors declare no conflict of interest.

Reference

  1. Pagonabarraga, J.; Arbelo, J.M.; Grandas, F.; Luquin, M.-R.; Martínez Martín, P.; Rodríguez-Oroz, M.C.; Valldeoriola, F.; Kulisevsky, J. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176. [Google Scholar] [CrossRef] [PubMed] [Green Version]

Share and Cite

MDPI and ACS Style

Pagonabarraga, J.; Arbelo, J.M.; Grandas, F.; Luquin, M.-R.; Martínez Martín, P.; Rodriguez-Oroz, M.C.; Valldeoriola, F.; Kulisevsky, J. Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176. Brain Sci. 2020, 10, 313. https://doi.org/10.3390/brainsci10050313

AMA Style

Pagonabarraga J, Arbelo JM, Grandas F, Luquin M-R, Martínez Martín P, Rodriguez-Oroz MC, Valldeoriola F, Kulisevsky J. Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176. Brain Sciences. 2020; 10(5):313. https://doi.org/10.3390/brainsci10050313

Chicago/Turabian Style

Pagonabarraga, Javier, José Matías Arbelo, Francisco Grandas, Maria-Rosario Luquin, Pablo Martínez Martín, Maria Cruz Rodriguez-Oroz, Francesc Valldeoriola, and Jaime Kulisevsky. 2020. "Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176" Brain Sciences 10, no. 5: 313. https://doi.org/10.3390/brainsci10050313

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop